Tagged with oncology

Spain Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to global chief commercial officer.   Schüberg got his first pharma job at Lundbeck in 1994 after serving in the Swedish…

Spain Esteve’s CEO outlines the transformation journey of the Spanish company after taking over in 2018, commenting on how the divestment of its generics business has helped the company lay the foundation of a specialty pharma player in CNS, oncology and ophthalmology. Staffan Schüberg, former EVP and Chief Commercial Officer at…

Spain The Vall d’Hebron Institute of Oncology (VHIO) is a Barcelona-based institute dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of patients. Its director, Dr Josep Tabernero, talks about VHIO’s four main lines of…

Global Writing in the February edition of DIA’s Global Forum magazine, Candice Del Rio of Curavit Clinical Research examines the applicability of decentralised clinical trials in oncology research, and their positive impact on both decreasing patient dropout rates and increasing patient engagement. Oncology represents the largest research area globally, with 6.5 percent…

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Global The oncology field has exploded in the past 20 years and pharma companies now have a wide range of approaches available to them as they look to identify, treat, and in some cases even cure, cancer patients. Here, five industry experts weigh in on the exciting new tools and technology…

Saudi Arabia Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing…

Denmark Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’ relevance to Servier as an innovation hub and home to its antibody centre of excellence.   Servier is actively looking…

Germany Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer patients eligible to receive Novartis’ CAR-T therapy in Germany.   There has been a big change in the last few…

USA Melanie Croce-Galis, RN, MPH explains the specificities of her work as patient engagement lead for Novartis Oncology in the US market, where significant disparities in patient access to information and to care throw up several challenges. Croce-Galis also outlines the work being done around CAR-T therapies and why integrating and…

China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021.   Since first joining the company back in 2002, Afonso held a variety of roles IT…